Clinical outcome and paravalvular leakage of the new balloon-expandable Edwards Sapien 3 valve in comparison to its predecessor model (Edwards Sapien XT) in patients undergoing transfemoral aortic valve replacement

Catheterization and Cardiovascular Interventions

Volumn 88, Issue 3, 2016, Pages 466-475

  Bocksch, Wolfgang ^a   Grossmann, Benita ^a   Geisler, Tobias ^a   Steeg, Martin ^a   Droppa, Michal ^a   Jorbenadze, Rezo ^a   Haap, Michael ^a   Gawaz, Meinrad ^a   Fateh Moghadam, Suzanne ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

aortic stenosis; balloon expandable valve; paravalvular leakage; residual aortic regurgitation; transfemoral aortic valve replacement

Indexed keywords

ACUTE KIDNEY FAILURE; AGED; AORTA DISEASE; AORTA STENOSIS; AORTA VALVE PROSTHESIS; AORTA VALVE REPLACEMENT; AORTIC BLEEDING; ARTICLE; BRAIN HEMORRHAGE; CARDIOVASCULAR MORTALITY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVICE SAFETY; DISEASE SEVERITY; FEMALE; FLUOROSCOPY; GUIDE WIRE; HEART VENTRICLE FIBRILLATION; HUMAN; IMAGE ANALYSIS; INCIDENCE; INTERMEDIATE RISK PATIENT; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PARAVALVULAR LEAK; PROSPECTIVE STUDY; SURGICAL RISK; THREE DIMENSIONAL IMAGING; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT OUTCOME; VERY ELDERLY;

EID: 84986917921     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.26562     Document Type: Article

References (31)

1. Leon MB, Smith CR, Mack M, et al., For the PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Eng J Med 2010;363:1597–1607.
2. Popma JJ, Adams DH, Reardon MJ, et al., For the CoreValve United States Clinical Investigators. Transcatheter aortic valve replacement using a self-expanding bioprosthesis in patients with severe aortic stenosis at extreme risk for surgery. J Am Coll Cardiol 2014;63:1972–1981.
3. Smith CR, Leon MB, Mack MJ, et al., For the PARTNER Trial Investigators. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 2011;364:2187–2198.
4. Adams DH, Popma JJ, Reardon MJ, et al., For the U.S. CoreValve Clinical Investigators. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med 2014;370:1790–1798.
5. nd Annual Scientific Session of the American College of Cardiology; March 10, 2013; San Francisco.
6. Kodali SK, Williams MR, Smith CR, et al., PARTNER Trial Investigators. Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med 2012;366:1686–1695.
7. Kodali S, Pibarot P, Douglas PS, et al. Paravalvular regurgitation after transcatheter aortic valve replacement with the Edwards Sapien Valve in the PARTNER trial: Characterizing patients and impact on outcomes. Eur Heart J 2015;36:449–456.
8. Binder RK, Rodés-Cabau J, Wood DA, et al. Transcatheter aortic valve replacement with the SAPIEN 3: A new balloon-expandable transcatheter heart valve. JACC Cardiovasc. Interv 2013;6:293–300.
9. Amat-Santos IJ, Dahou A, Webb J, et al. Comparison of hemodynamic performance of the balloon-expandable Sapien 3 versus Sapien XT transcatheter valve. Am J Cardiol 2014;114:1075–1082.
10. Kappetein AP, Head SJ, Généreux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: The Valve Academic Research Consortium-2 consensus document. J Am Coll Cardiol 2012;60:1438–1454.
11. Nishimura RA, Otto CM, Bonow RO, et al., American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63:2438–2488.
12. Vahanian A, Alfieri O, Andreotti F, et al., For the ESC Committee for Practice Guidelines (CPG); Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC); European Association for Cardio-Thoracic Surgery (EACTS). Guidelines on the management of valvular heart disease (version 2012): The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg 2012;42:S1–S44.
13. Achenbach S, Delgado VJ, Hausleiter J, Schoenhagen P, Min JK, Leipsic JA. SCCT expert consensus document on computed tomography imaging before transcatheter aortic valve implantation (TAVI)/transcatheter aortic valve replacement (TAVR). J Cardiovasc Comput Tomogr 2012; 6:366–380.
14. Vaitkus PT, Wang DD, Greenbaum A, Guerrero M, ÓNeill W. Assessment of a novel software tool in the selection of aortic valve prosthesis size for transcatheter aortic valve replacement. J Invasive Cardiol 2014;26:328–332.
15. Kasel AM, Cassese S, Bleiziffer S, et al. Standardized imaging for aortic annular sizing: Implications for transcatheter valve selection. JACC Cardiovasc Imaging 2013;6:249–262.
16. Kasel AM, Shivaraju AS, Schneider S, et al. Standardized methodology for transfemoral transcatheter aortic valve replacement with the Edwards Sapien XT valve under fluoroscopy guidance. J Invasive Cardiol 2014;26:451–461.
17. Baumgartner H, Hung J, Bermejo J, et al., American Society of Echocardiography, European Association of Echocardiography. EAE/ASE. Echocardiographic assessment of valve stenosis: EAE/ASE recommendation for clinical practice. Eur J Echocardiogr 2009;10:1–25.
18. Lang RM, Bierig M, Devereux RB, et al. Chamber Quantification Writing Group, American Society of Echocardiography's Guidelines and Standards Committee, European Association of Echocardiography. Recommendation for chamber quantification: A report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with European Association of echocardiography, a branch of the European Society of cardiology. J Am Soc Echocardiogr 2005;18:1440–1463.
19. Hahn RT, Pibarot P, Stewart WJ, et al. Comparison of transcatheter and surgical aortic valve replacement in severe aortic stenosis: A longitudinal study of echocardiography parameters in cohort A of the PARTNER trial (placement of aortic transcatheter valves). J Am Coll Cardiol 2013;61:2514–2521.
20. Webb J, Gerosa G, Lefèvre T, et al. Multicenter evaluation of a next-generation balloon-expandable transcatheter aortic valve. J Am Coll Cardiol 2014;64:2235–2243.
21. Abdel-Wahab M, Mehilli J, Frerker C, et al., For the CHOICE Investigators,. Comparison of balloon-expandable vs self-expandable valves in patients undergoing transcatheter aortic valve replacement: The CHOICE randomized clinical trial. JAMA 2014;311:1503–1514.
22. Abdel-Wahab M, Neumann FJ, Mehilli J, et al., Choice Investigators. 1-Year outcomes after transcatheter aortic valve replacement with balloon-expandable valves. Results from the CHOICE Randomized Clinical Trial. J Am Coll Cardiol 2015;66:791–800.
23. Nombela-Franco L, Webb JG, de Jaegere PP, et al. Timing, predictive factors, and prognostic value of cerebrovascular events in a large cohort of patients undergoing transcatheter aortic valve implantation. Circulation 2012;126:3041–3053.
24. Généreux P, Webb JG, Svensson LG, et al., For the PARTNER Trial Investigators. Vascular complications after transcatheter aortic valve replacement: Insights from the PARTNER (Placement of AoRTic TraNscathetER Valve) trial. J Am Coll Cardiol 2012;60:1043–1052.
25. Schymik G, Schroefel H, Schymik JS, et al. Acute and late outcomes of Transcatheter Aortic Valve Implantation (TAVI) for the treatment of severe symptomatic aortic stenosis in patients at high- and low-surgical risk. J Interv Cardiol 2012;25:364–374.
26. Bagur R, Webb JG, Nietlispach F, et al. Acute kidney injury following transcatheter aortic valve implantation: Predictive factors, prognostic value, and comparison with surgical aortic valve replacement. Eur Heart J 2010;31:865–874.
27. Schymik G, Schroefel H, Heimeshoff M, et al. How to adapt the implantation technique for the new SAPIEN 3 transcatheter heart valve design. J Interv Cardiol 2015;28:82–89.
28. Urena M, Webb JG, Tamburino C, et al. Permanent pacemaker implantation after transcatheter aortic valve implantation: Impact on late clinical outcomes and left ventricular function. Circulation 2014;129:1233–1243.
29. Yang TH, Webb JG, Blanke P, et al. Incidence and severity of paravalvular aortic regurgitation with multidetector computed tomography nominal area oversizing or undersizing after transcatheter heart valve replacement with the Sapien 3. A Comparison with the Sapien XT. JACC Cardiovasc Interv 2015;3:462–471.
30. Schofer J, Colombo A, Klugmann S, et al. Prospective multicenter evaluation of the direct flow medical transcatheter aortic valve. J Am Coll Cardiol 2014;63:763–768.
31. Meredith IT, Worthley SG, Whitbourn RJ, et al. Transfemoral aortic valve replacement with the repositionable Lotus Valve System in high surgical risk patients: The Reprise 1 study. Eurointervention 2014;9:1264–1270.